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ABSTRACT
Aims The overall aim of the new national newborn
programme is to identify infants at risk of sickle cell
disease to allow early detection and to minimise deaths
and complications.
Methods Universal screening for sickle cell disease was
introduced in England between September 2003 and
July 2006. The 13 newborn laboratories each screen
between 25000 and 110000 babies a year using the
existing dried bloodspot cards. The speciﬁed conditions
to be screened for include sickle cell anaemia (Hb SS),
Hb SC disease, Hb S/b thalassaemia, Hb S/D
Punjab and
Hb S/O
Arab. Data are reported on screening results by
ethnic group and geographical area.
Results The prevalence of screen positive results across
England is 1:2000. There is a 25-fold variation by
geographical area. African babies make up 61% of all
screen positive results despite representing only 4% of
total births. Combined carrier rates vary widely by
ethnicity, from 1.85 per 1000 (1:540) in ‘White British’ to
145 per 1000 (1:7) in ‘African’ babies. Refusal rates for
screening show variation by ethnicity.
Conclusions These results provide useful information
both about the frequency of these conditions and the
carrier state and their geographic and ethnic distribution
across England. This can be used to reﬁne counselling
information and are also useful to target and plan
services and public information.
AIMS
The overall aim of the recently introduced national
newborn programme is to identify infants at risk of
sickle cell disease to allow early detection and to
minimise deaths and complications through early
treatment and care. Screening is now offered to all
babies in England irrespective of ethnicity at
5e8 days of age as part of the pre-existing newborn
dried blood-spot screening programme; imple-
mentation is planned for Scotland in 2010. We
report the frequency of suspected disease rates for
different parts of the country and for the ﬁrst time
we report newborn carrier data broken down by
ethnicity using the categories recorded on the dried
bloodspot (Guthrie) card. This is important infor-
mation for those who have to counsel such fami-
lies. The reported carrier rate for England as a whole
is 15/1000. The frequency of diagnosis of sickle cell
disease suggests that it should be given a higher
priority in medical and nursing education and in
NHS service planning and provision. The scale of
need for genetic counselling arising from this
programme is also emphasised.
METHODS
Screening for sickle cell disease was introduced in
England between September 2003 and July 2006,
building on the existing patchy screening arrange-
ments which covered about 15% of England (in
parts of London and the West Midlands).
The policy adopted by the National Screening
Committee (NSC) was to introduce universal resi-
dent based screening of all infants using the
bloodspot card and to discontinue catchment based
cord blood samples.
1 The newborn laboratory
service providing the screening in England now
consists of 13 centralised biochemistry newborn
screening laboratoriesdeach screening between
25000 and 110000 babies a year. For sickle cell
screening, second line testing of all positive results
is performed, either within the screening labora-
tory, or by a specialist haematology laboratory
within the same hospital trust or elsewhere. Two
methods of analysis are applied to all screen-posi-
tive results obtained from dried blood spot samples
to ensure high speciﬁcity: either high performance
liquid chromatography or iso-electric focussing
(further details are included in our laboratory
handbook).
2 In addition to screening for sickle cell
disease, these biochemistry laboratories perform
newborn screening for phenylketonuria, congenital
hypothyroidism, cystic ﬁbrosis and medium chain
acyl CoA dehydrogenase (MCADD).
3
The screening programme speciﬁes the condi-
tions to be screened for and recommends speciﬁc
methods to be used.
2 The conditions screened for
because of the potential beneﬁt are: sickle cell
anaemia (Hb SS), Hb SC disease, Hb S/b thalas-
saemia, Hb S/D
Punjab and Hb S/O
Arab.H bS /
hereditary persistence of foetal haemoglobin is also
included as it needs to be distinguished from Hb SS
and S/b or db thalassaemia although it is not in
itself a condition for which there is proven beneﬁt
in screening. Currently the UK NSC does not
support screening for b thalassaemia.
A detailed implementation plan was developed
which included training of staff responsible for
taking samples (predominantly midwives) and
providing laboratory set-up costs, development of
materials for parents, recruitment of counsellors
and funding of laboratories as described elsewhere.
4 5
Standards for the linked newborn and antenatal
programme
6 and for the overall bloodspot
programme
3 are available in various publications.
The NSC supported the recommendation by the
programme that, in line with pre-existing practice
in areas already undertaking newborn screening,
carriers of the main haemoglobins including S, C,
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Original articleD, E and others should be reported to parents. This was
a controversial area with many clinical geneticists considering
that this information should be withheld, but the debate has
helped to move thinking forward on this issue. The UK decision
is in line with the recent review undertaken in the USA and
takes account of the fact that the aim of the programme is to
detect infants affected by conditions for which there is good
evidence of beneﬁt.
Screening for carriers is not the primary aim of the
programme, but these are detected using our chosen technology.
In the UK it was not considered ethical to withhold this infor-
mation if parents wished to have it.
7 8 Carriers of the common
haemoglobin variants (S, C, D and E) are therefore reported to
parents with speciﬁc supporting materials aimed of parents with
an infant rather than adults considering a pregnancy.
9 Coun-
selling is offered to ensure parents understand that their child is
healthy and the difference between carrier state and disease, the
distinction between the S carrier status (which is clinically
important to know) and other carrier statuses (which are
unlikely to be clinically important but have genetic relevance).
9
Unlike antenatal screening, newborn screening methods do not
reliably identify all thalassaemia carriers although parents who
are carriers often want to know this information. Recently
published work has suggested that some b thalassaemia carriers
may be detected by their low levels of Hb A at birth.
10
Demographic data are recorded on the blood spot card by the
midwife who takes the sample, including ethnic data selected
from a table printed on the back of the card. This ethnic data
ﬁeld is not completed in all cases and has not been available from
one laboratory for the period reported here.
Data are collected from all laboratories, checked and discussed
with the providing laboratory to keep inconsistencies to
a minimum. The data are used to assist in planning counselling
and clinical services and to inform antenatal prevalence esti-
mates and local screening policy and service planning. The time
period of the data collections is the two ﬁnancial years of 2005/
06 and 2006/2007.
RESULTS
The prevalence of screening results indicating likely sickle cell
disease (screen positive results) varies widely (table 1). It ranges
from 3 per 1000 in South East London (ie, about 1:330 babies
have a screen positive result) to 0.12 per 1000 in Cumbria and
Lancashireda 25-fold variation in prevalence. Within London
the prevalence is highest in South East London at 3/1000 and
lowest in North West London at 1/1000. Other areas with higher
rates of 0.4e0.5/1000 include Leicester and Northants,
Bedfordshire, Birmingham, Essex and Greater Manchester.
Overall babies recorded as Black African make up 61% of all the
sickle cell disease suspected results despite representing only 4%
of total births. Overall screen positive disease prevalence rate is
1:2000 for England.
5
Figure 1 shows that combined carrier rates also vary widely by
ethnicity from 1.85 per 1000 (1:540) in those babies recorded as
‘White British’ to 145 per 1000 (1:7) for ‘Black African’ babies.
Figure 2, showing refusal rates for screening, shows that
several populations such as the ‘any other white background’
(1:940), ‘Black Caribbean’ (1:840) and ‘not stated’ (1:880)
populations appear to have a signiﬁcantly higher rate of refusal
of screening than the ‘White British’ (1:3150) category with CIs
not overlapping the ‘White British’ category. Overall about 300
refusals are documented each year, and for these cases a blank
Table 1 Rates of signiﬁcant conditions* by strategic health
authoritiesy: April 2005 to March 2007
Results for newborns: April
2005 to March 2007
Rate per
1000 babies
screened No.
No. of
babies
screened
County Durham and Tees Valley z <5 23228
Don’t know z <5 29641
Hampshire and Isle of Wight z <5 23134
North and East Yorkshire and Northern
Lincolnshire
z <5 32781
South West Peninsula z <5 31073
Surrey and Sussex z <5 58190
Trent z <5 58814
Dorset and Somerset 0 0 15931
Cumbria and Lancashire 0.12 5 42632
Norfolk, Suffolk and Cambridgeshire 0.12 5 41945
Cheshire and Merseyside 0.14 8 56655
Coventry, Warwickshire, Herefordshire
and Worcestershire
0.14 5 35355
Shropshire and Staffordshire 0.15 5 33400
Northumberland, Tyne and Wear 0.19 5 26093
Avon, Gloucestershire and Wiltshire 0.23 10 43516
Thames Valley 0.24 6 24701
Kent and Medway 0.25 10 39764
South Yorkshire 0.26 8 30881
West Yorkshire 0.32 18 55954
Greater Manchester 0.38 27 70211
Essex 0.39 15 38610
Birmingham and the Black Country 0.43 28 65150
Bedford and Hertfordshire 0.44 19 43239
Leicestershire, Northamptonshire and
Rutland
0.53 20 38062
London North West 0.99 55 55514
London South West 1.25 49 39044
London North Central 1.41 54 38231
London North East 2.18 120 55050
London South East 3.05 158 51815
England 0.54 651 1198614
Note that Portsmouth provided data from April 2006 and Oxford from July 2006.
*Signiﬁcant conditions comprise the following results: FS, FSC, FS other and FE (F, foetal
haemoglobin; S, S haemoglobin; C, C haemoglobin; E, E haemoglobin).
yPre July 2006.
zSample too small.
Figure 1 Carrier rates by ethnic category: April 2005 to March 2007.
J Clin Pathol 2010;63:626e629. doi:10.1136/jcp.2010.077560 627
Original articlecard is sent to the laboratory to ensure that this information is
documented on all records so that a test may still be performed
if clinical suspicion is raised or if the child subsequently becomes
ill. Almost exclusively refusals are for screening for all ﬁve
conditions and not speciﬁcally a refusal for sickle cell disease
screening. To date, to our knowledge, none of these refusals have
been babies already identiﬁed by antenatal screening as at high
risk of being affected. For infants at a 1:4 or higher risk the
clinical policy is to offer liquid blood sample testing in advance
of the bloodspot screen which is still offered (see page 4 of the
programme laboratory handbook).
2
Table 2 shows that different ethnic groups have different
patterns of carrier rates, with haemoglobin D being predomi-
nantly seen in the Indian and Pakistani populations and
haemoglobin E seen in the Bangladeshi population.
CONCLUSION
These results from the newborn screening programme provide
useful objective information, both about the frequency of these
conditions and the carrier state and their variable geographic and
ethnic distribution across England. They give ratios of condi-
tions and carrier frequencies by ethnic group which can be used
by the programme to reﬁne counselling information for indi-
viduals and couples as recently recommended by Kai et al.
11
They are also useful to target and plan services and public
information.
The limitations of the data are that it is based on ethnicity
data ascertained by midwives and recorded on the bloodspot
card rather than on a detailed family origin questionnaire, and
also that ethnic data were not recorded in about 13% of samples.
Despite this, the overall pattern and distribution of disease and
carrier rates expected is clearly shown. A second limitation of
the data is that these are screening and not diagnostic results,
but as reported elsewhere the screening methods used are highly
speciﬁc and sensitive, and results are unlikely to be signiﬁcantly
changed when conﬁrmatory tests are completed.
5
None of these limitations are likely to materially affect the
main ﬁndings of the general prevalence of the conditiondnow
about 1:2000 affected births in England: it is as common as
cystic ﬁbrosis. The signiﬁcant contribution that the Black
African, rather than the African-Caribbean population makes to
the disease is of note. The data also show the signiﬁcant burden
that these conditions are likely to place on the London NHS.
Figure 2 Refusal rates per 1000 babies screened: April 2005 to March
2007.
Table 2 Carrier rates by ethnic category* and Hb type: April 2005 to March 2007
Results for newborns:
April 2005 to March 2007
FAS FAC FADy FAE Other Carriers
No.
Rate per
1000 babies
screened No.
Rate per
1000 babies
screened No.
Rate per
1000 babies
screened No.
Rate per
1000 babies
screened No.
Rate per
1000 babies
screened
No. of
babies
screened
White British 376 0.55 121 0.18 249 0.37 77 0.11 435 0.64 679911
Bangladeshi 10 0.68 8 0.54 42 2.86 610 41.54 34 2.32 14686
Pakistani 28 0.87 5 0.15 264 8.18 61 1.89 75 2.32 32289
Chinese 7 1.44 1 0.21 0 0.00 22 4.52 14 2.88 4863
Any other White background 79 1.95 19 0.47 20 0.49 13 0.32 36 0.89 40469
White Irish 4 2.02 0 0.00 0 0.00 1 0.51 1 0.51 1978
White and Asian 25 2.68 2 0.21 21 2.25 149 15.98 17 1.82 9324
Any other Asian background 40 3.39 3 0.25 42 3.56 77 6.52 24 2.03 11806
Indian 115 4.62 9 0.36 176 7.07 43 1.73 57 2.29 24900
Not stated 1290 9.58 287 2.13 137 1.02 145 1.08 186 1.38 134693
Any other ethnic category 432 17.18 77 3.06 34 1.35 90 3.58 54 2.15 25145
Any other mixed background 339 21.00 99 6.13 17 1.05 70 4.34 23 1.42 16141
White and Black Caribbean 515 49.15 157 14.98 5 0.48 27 2.58 15 1.43 10479
White and Black African 422 75.51 68 12.17 1 0.18 1 0.18 11 1.97 5589
Any other Black background 273 81.66 64 19.14 4 1.20 1 0.30 11 3.29 3343
Black Caribbean 1093 86.80 383 30.42 2 0.16 0 0.00 26 2.06 12592
Black African 4952 120.88 863 21.07 8 0.20 4 0.10 102 2.49 40965
Total 10000 9.35 2166 2.03 1022 0.96 1391 1.30 1121 1.05 1069173
Birmingham was unable to provide denominators by ethnic category due to variations in coding of ethnic category and laboratory software constraints and their data has been taken out of this
table. About 11% of all babies, 10% of carriers and approx 6% of all affected babies are tested in Birmingham.
Note that Portsmouth provided data from April 2006 and Oxford from July 2006 only.
*Ethnic category as it appears on the Guthrie card.
ySince there are many ‘D’ variants and characterisation may take some time, it is recommended that all ‘D’ variants with the characteristics of D Punjab (the only clinically signiﬁcant variant)
are assumed to be clinically signiﬁcant and reported. DNA analysis or mass spectrometry can be used to elucidate the diagnosis.
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Original articleThese objective ﬁgures should replace previous estimates of the
scale of these conditions which are now out of date. They suggest
that the management and care of haemoglobinopathies as a long
term condition needs to move from its ‘orphan’ status into the
mainstream of the NHS commissioning and clinical agenda as an
important addition to the inequalities in healthcare agenda. The
huge variation in the condition by ethnicity shown by these
ﬁgures arguably explains why the condition has not received the
attention it merits as the groups affected are often marginalised
within UK society. Awelcome recent development which may be
helping to raise the proﬁle of these conditions in the NHS is the
establishment of an All Party Parliamentary group.
The other issue that these ﬁgures raise is the frequency of the
carrier state and the ongoing challenge to record such informa-
tion accurately, in primary care records, so that it is available
when needed and repeat testing is avoided. In the case of S
carrier status, this is important information for parents and
children as sickling does occur, albeit rarely, under stress of
deoxygenation such as during surgery, at high altitude and
during extreme physical activity.
12 13 This information is not
solely relevant for reproductive reasons but also for clinical
reasons, and in a child this latter point is the important issue.
We hope that by presenting objective information, which
should be read alongside other information, the clinical
community responsible for education of future clinicians and for
developing services will act to support the obvious clinical needs
shown, and will ensure that genetic issues are considered
alongside clinical needs.
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Take-home messages
< In England, sickle cell disease is considerably more common
than usually quoted, with a birth prevalence of 1:2000 (more
common than cystic ﬁbrosis¼1:2500), and an S carrier rate of
almost 1% in newborn babies.
< There is wide (25-fold) geographical variation in the frequency
of sickle cell disease. Most affected babies are in London and
other large urban centres, but sickle cell disease is occurring
in all parts of England, including areas where previously the
disease was unreported and thought to be ‘not a problem
here’.
< For the ﬁrst time reliable carrier rates by reported ethnicity
give objective information by ethnic group to help those who
counsel individuals and couples about their risk of sickle cell
conditions. This includes the fact that 1:800 babies reported
as ‘White British’ is a carrier of the S, C, D or E gene.
< Collecting this ethnicity data has also been very valuable in
showing variation by ethnicity in refusal rates, and this should
continue to be monitored.
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